RESUMEN
The most used cancer serum biomarker is the CA125 immunoassay for ovarian cancer that detects the mucin glycoprotein MUC16. Several monoclonal antibodies (mAbs) including OC125 and M11 are used in CA125 assays. However, despite considerable efforts, our knowledge of the molecular characteristics of the recognized epitopes and the role played by glycosylation has remained elusive. Here a comprehensive set of recombinant MUC16 tandem repeats (TRs) expressed in glycoengineered mammalian cells and E. coli, together with overlapping peptides, was used to probe antigen-binding epitopes. We present a complete analysis of N- and O-glycosylation sites of a MUC16 TR expressed in CHO cells and demonstrate that neither N- nor O-glycosylation appear to substantially influence binding of OC125 and M11 mAbs. A series of successive N- and C-terminal truncations of a MUC16 TR construct expressed in E. coli narrowed down the epitopes for OC125 and M11 to a segment containing parts of two consecutive SEA domains with a linker. Thus, a complete SEA domain is not required. These findings suggest that binding epitopes of mAbs OC125 and M11 are dependent on conformation but not on glycosylation. The availability of recombinant TR constructs with and without aberrant glycosylation now opens the way for vaccine studies.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/química , Antígeno Ca-125/inmunología , Proteínas de la Membrana/inmunología , Animales , Antígeno Ca-125/química , Antígeno Ca-125/metabolismo , Células CHO , Cricetinae , Cricetulus , Mapeo Epitopo , Glicosilación , Proteínas de la Membrana/química , Proteínas de la Membrana/metabolismo , Ratones , Unión Proteica , Procesamiento Proteico-Postraduccional , Estructura Terciaria de ProteínaRESUMEN
Cancer-associated autoantibodies hold promise as sensitive biomarkers for early detection of cancer. Aberrant post-translational variants of proteins are likely to induce autoantibodies, and changes in O-linked glycosylation represent one of the most important cancer-associated post-translational modifications (PTMs). Short aberrant O-glycans on proteins may introduce novel glycopeptide epitopes that can elicit autoantibodies because of lack of tolerance. Technical barriers, however, have hampered detection of such glycopeptide-specific autoantibodies. Here, we have constructed an expanded glycopeptide array displaying a comprehensive library of glycopeptides and glycoproteins derived from a panel of human mucins (MUC1, MUC2, MUC4, MUC5AC, MUC6 and MUC7) known to have altered glycosylation and expression in cancer. Seromic profiling of patients with colorectal cancer identified cancer-associated autoantibodies to a set of aberrant glycopeptides derived from MUC1 and MUC4. The cumulative sensitivity of the array analysis was 79% with a specificity of 92%. The most prevalent of the identified autoantibody targets were validated as authentic cancer immunogens by showing expression of the epitopes in cancer using novel monoclonal antibodies. Our study provides evidence for the value of glycopeptides and other PTM-peptide arrays in diagnostic measures.
Asunto(s)
Biomarcadores de Tumor/análisis , Neoplasias Colorrectales/sangre , Glicopéptidos/sangre , Mucinas/sangre , Análisis por Matrices de Proteínas , Anticuerpos Monoclonales/inmunología , Autoanticuerpos/inmunología , Biomarcadores de Tumor/inmunología , Estudios de Casos y Controles , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/inmunología , Ensayo de Inmunoadsorción Enzimática , Epítopos/análisis , Femenino , Glicopéptidos/inmunología , Glicosilación , Humanos , Técnicas para Inmunoenzimas , Masculino , Persona de Mediana Edad , Mucinas/inmunología , Pronóstico , Procesamiento Proteico-Postraduccional , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismoRESUMEN
Autoantibodies to cancer antigens hold promise as biomarkers for early detection of cancer. Proteins that are aberrantly processed in cancer cells are likely to present autoantibody targets. The extracellular mucin MUC1 is overexpressed and aberrantly glycosylated in many cancers; thus, we evaluated whether autoantibodies generated to aberrant O-glycoforms of MUC1 might serve as sensitive diagnostic biomarkers for cancer. Using an antibody-based glycoprofiling ELISA assay, we documented that aberrant truncated glycoforms were not detected in sera of cancer patients. An O-glycopeptide microarray was developed that detected IgG antibodies to aberrant O-glycopeptide epitopes in patients vaccinated with a keyhole limpet hemocyanin-conjugated truncated MUC1 peptide. We detected cancer-associated IgG autoantibodies in sera from breast, ovarian, and prostate cancer patients against different aberrent O-glycopeptide epitopes derived from MUC1. These autoantibodies represent a previously unaddressed source of sensitive biomarkers for early detection of cancer. The methods we have developed for chemoenzymatic synthesis of O-glycopeptides on microarrays may allow for broader mining of the entire cancer O-glycopeptidome.
Asunto(s)
Autoanticuerpos/análisis , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/inmunología , Epítopos/análisis , Glicopéptidos/inmunología , Presentación de Antígeno/fisiología , Autoanticuerpos/sangre , Neoplasias de la Mama/sangre , Neoplasias de la Mama/inmunología , Carcinoma/sangre , Carcinoma/inmunología , Estudios de Casos y Controles , Ensayos Clínicos Fase I como Asunto , Ensayo de Inmunoadsorción Enzimática/métodos , Mapeo Epitopo/métodos , Femenino , Humanos , Inmunización , Masculino , Modelos Biológicos , Mucina-1/química , Mucina-1/inmunología , Neoplasias Ováricas/sangre , Neoplasias Ováricas/inmunología , Biblioteca de Péptidos , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/inmunología , Análisis por Matrices de Proteínas/instrumentación , Análisis por Matrices de Proteínas/métodosRESUMEN
The cell membrane mucin MUC1 is over-expressed and aberrantly glycosylated in many cancers, and cancer-associated MUC1 glycoforms represent potential targets for immunodiagnostic and therapeutic measures. We have recently shown that MUC1 with GalNAcalpha1-O-Ser/Thr (Tn) and NeuAcalpha2-6GalNAcalpha1-O-Ser/Thr (STn) O-glycosylation is a cancer-specific glycoform, and that Tn/STn-MUC1 glycopeptide-based vaccines can override tolerance in human MUC1 transgenic mice and induce humoral immunity with high specificity for MUC1 cancer-specific glycoforms (Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, et al. 2006. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology. 16:96-107). In order to further characterize the immune response to Tn/STn-MUC1 glycoforms, we generated monoclonal antibodies with specificity similar to the polyclonal antibody response found in transgenic mice. In the present study, we define the immunodominant epitope on Tn/STn-MUC1 glycopeptides to the region including the amino acids GSTA of the MUC1 20-amino acid tandem repeat (HGVTSAPDTRPAPGSTAPPA). Most other MUC1 antibodies are directed to the PDTR region, although patients with antibodies to the GSTA region have been identified. A panel of other MUC1 glycoform-specific monoclonal antibodies was included for comparison. The study demonstrates that the GSTA region of the MUC1 tandem repeat contains a highly immunodominant epitope when presented with immature short O-glycans. The cancer-specific expression of this glycopeptide epitope makes it a prime candidate for immunodiagnostic and therapeutic measures.
Asunto(s)
Epítopos Inmunodominantes/química , Mucina-1/inmunología , Neoplasias/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/inmunología , Mapeo Epitopo , Femenino , Glicopéptidos/química , Glicopéptidos/inmunología , Humanos , Sueros Inmunes/inmunología , Epítopos Inmunodominantes/inmunología , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Mucina-1/química , Secuencias Repetitivas de AminoácidoRESUMEN
Present therapies cannot cure the large majority of patients with multiple myeloma (MM) and therefore new treatment strategies are imperative. This study analysed the different glycosylation profiles of Mucin-1 (MUC1) on MM and acute myeloid leukaemia (AML) cells using a series of anti-MUC1 antibodies. Seventy-three per cent of the MM patients had plasma cells that expressed the fully glycosylated forms of MUC1. In contrast to controls, normal bone marrow cells and AML cells, the differentiation-dependent and cancer-associated glycoforms of MUC1 were present on 59% and 36% MM tumour cells respectively. This indicated that aberrantly glycosylated MUC1 is a potential immunotherapeutic target in MM patients.
Asunto(s)
Antígenos de Neoplasias/metabolismo , Mucinas/metabolismo , Mieloma Múltiple/metabolismo , Proteínas de Neoplasias/metabolismo , Enfermedad Aguda , Anticuerpos Antineoplásicos/metabolismo , Antígenos de Neoplasias/inmunología , Médula Ósea/inmunología , Citometría de Flujo , Glicosilación , Humanos , Leucemia Mieloide/metabolismo , Mucina-1 , Mucinas/inmunología , Mieloma Múltiple/inmunologíaRESUMEN
Covalent attachment of polyethylene glycol, PEGylation, has been shown to prolong the half-life and enhance the pharmacodynamics of therapeutic proteins. Current methods for PEGylation, which rely on chemical conjugation through reactive groups on amino acids, often generate isoforms in which PEG is attached at sites that interfere with bioactivity. Here, we present a novel strategy for site-directed PEGylation using glycosyltransferases to attach PEG to O-glycans. The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues. The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.
Asunto(s)
Acetilgalactosamina/análogos & derivados , Citocinas/química , Polietilenglicoles/química , Acetilgalactosamina/química , Citocinas/biosíntesis , Citocinas/uso terapéutico , Escherichia coli , Glicosilación , Humanos , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/química , Proteínas Recombinantes/uso terapéuticoRESUMEN
The MUC1 mucin represents a prime target antigen for cancer immunotherapy because it is abundantly expressed and aberrantly glycosylated in carcinomas. Attempts to generate strong humoral immunity to MUC1 by immunization with peptides have generally failed partly because of tolerance. In this study, we have developed chemoenzymatic synthesis of extended MUC1 TR glycopeptides with cancer-associated O-glycosylation using a panel of recombinant human glycosyltransferases. MUC1 glycopeptides with different densities of Tn and STn glycoforms conjugated to KLH were used as immunogens to evaluate an optimal vaccine design. Glycopeptides with complete O-glycan occupancy (five sites per repeat) elicited the strongest antibody response reacting with MUC1 expressed in breast cancer cell lines in both Balb/c and MUC1.Tg mice. The elicited humoral immune response showed remarkable specificity for cancer cells suggesting that the glycopeptide design holds promise as a cancer vaccine. The elicited immune responses were directed to combined glycopeptide epitopes, and both peptide sequence and carbohydrate structures were important for the antigen. A MAb (5E5) with similar specificity as the elicited immune response was generated and shown to have the same remarkable cancer specificity. This antibody may hold promise in diagnostic and immunopreventive measures.